Piramal Pharma Q1 FY27: Revenue up 17%, loss narrows

What Piramal Pharma reported for Q1 FY27

Piramal Pharma Ltd. reported a narrower consolidated net loss for the quarter ended June 30, 2026 (Q1 FY27), supported by double-digit growth in revenue and a sharp improvement in operating profitability. The company posted a consolidated net loss of ₹69.4 crore, compared with a loss of ₹81.7 crore in the corresponding quarter last year. Revenue from operations rose 17.4% year-on-year to ₹2,270 crore, up from ₹1,934 crore a year earlier.

The quarterly filing also highlighted that operating performance improved meaningfully during the period. EBITDA jumped 82.9% year-on-year to ₹195 crore, compared with ₹107 crore in the year-ago quarter. The EBITDA margin expanded to 8.6% from 5.5%, reflecting improved operating leverage and profitability.

Earnings context: growth despite a quarterly loss

The headline takeaway was the combination of higher revenue and a narrower loss. While Piramal Pharma remained in a consolidated net loss position for the quarter, the year-on-year reduction indicates improving operating strength relative to the prior year period. The company’s commentary pointed to strong momentum in its CDMO and hospital generics businesses as key contributors to the revenue lift.

On the margin front, the rise in EBITDA and expansion in EBITDA margin stood out because the company delivered this improvement even with ongoing operational issues at one of its locations. The improvement in margin from 5.5% to 8.6% shows that cost and mix benefits were visible at the operating level during the quarter.

Operational developments: Ahmedabad disruption and US FDA clearance

Alongside the financial numbers, Piramal Pharma said it is actively managing local operational disruptions. This includes a temporary suspension of its Ahmedabad facilities due to severe flooding. The company also noted progress on the regulatory side through the successful US FDA clearance of its Sellersville facility in the United States.

For investors, these operational updates matter because they affect near-term continuity and medium-term capacity utilisation. A temporary suspension can pressure shipments and schedules in the short term, while regulatory clearances can support business normalisation and customer confidence.

Standalone revenue trend mentioned in the update

The market snapshot included a standalone revenue figure as well. Standalone revenue from operations for the quarter stood at ₹1,124.95 crore, up from ₹969.88 crore in the corresponding quarter last year. The article also quantified this growth at approximately 15.99% year-on-year.

These standalone numbers sit alongside the consolidated picture and provide another lens on performance for the period. However, the headline results and margin commentary in the update were anchored to the consolidated income statement.

Conference call and near-term investor focus

The article noted that market focus will shift to a scheduled earnings conference call on July 30, 2026. Management is expected to outline its recovery timeline for CDMO order flows and discuss broader margin trends for the rest of FY27.

Separately, the update also referenced that the board will meet on July 29, 2026 to consider unaudited standalone and consolidated results for Q1 FY27. With the results and call clustered around these dates, investors typically watch for clarity on operational normalisation, order flow visibility, and margins.

Other datapoints cited: debt, market cap and price snapshots

A “Quick Details” section in the article listed several metrics including net debt (latest quarter) of ₹4,296 crore. It also cited a market capitalisation of ₹24,197.23 crore and a current market price (CMP) of ₹181.75.

The broader text also included additional price and market-cap snapshots, including a reference to Piramal Pharma shares trading at ₹168 with a market capitalisation of ₹22,393 crore, and another snapshot showing “Current Price ₹176”. Since these figures appear as separate market snapshots in the source text, they should be read as point-in-time references rather than a single consistent quote.

Acquisition and currency tailwind points referenced

The article stated that Q1 FY27 revenue growth was expected to benefit from favourable INR depreciation of approximately 12% to 14% against the USD compared to Q1 FY26. It also referenced the first full quarter contribution from the Kenalog acquisition, which targets annualised revenues of US$10 million to US$10 million.

The acquisition was said to be completed effective April 1, 2026 for an upfront payment of US$15 million plus up to US$15 million in contingent consideration. These details were presented as part of the contextual factors around the quarter.

Key numbers at a glance

Why this quarter matters for the stock and the sector

For the market, the combination of revenue growth and improving operating profitability can reshape how investors track the company’s earnings trajectory, especially when margins move up sharply year-on-year. At the same time, the company’s note on the Ahmedabad flooding disruption adds an operational variable investors will monitor for any knock-on effects on production timelines.

The US FDA clearance of the Sellersville facility is a separate but meaningful operational milestone, since regulatory outcomes can influence the continuity of supply and the ability to service customers in regulated markets. With the July 30, 2026 conference call approaching, investors are likely to focus on management’s specifics around CDMO order flow recovery and margin direction for FY27, as referenced in the article.

Conclusion

Piramal Pharma’s Q1 FY27 showed higher consolidated revenue, a sharp jump in EBITDA, and a narrower net loss compared with the same quarter last year. The quarter also featured operational cross-currents, including a temporary suspension of Ahmedabad facilities due to flooding and US FDA clearance for the Sellersville site. The next key event on the calendar is the earnings conference call scheduled for July 30, 2026, where management is expected to discuss CDMO order flows and margin trends for the rest of FY27.